Related Experiment Video

Updated: Aug 14, 2026

Retinal Pathophysiological Evaluation in a Rat Model
09:11

Retinal Pathophysiological Evaluation in a Rat Model

Published on: May 6, 2022

Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy

H P Hammes1, S Martin, K Federlin

  • 1III. Medizinische Klinik, Justus-Liebig-Universität, Giessen, Federal Republic of Germany.

Proceedings of the National Academy of Sciences of the United States of America
|December 15, 1991
PubMed

Insights

Advanced glycosylation products contribute to diabetic retinopathy by causing retinal capillary damage. Aminoguanidine, an inhibitor, significantly reduced these products and prevented characteristic diabetic retinopathy lesions in rats.

Area of Science:

  • Ophthalmology
  • Endocrinology
  • Pathology

Background:

  • Diabetic retinopathy is characterized by retinal capillary closure due to hyperglycemia.
  • The precise mechanisms driving this pathological process remain unclear.
  • Advanced glycosylation end-products (AGEs) are implicated in diabetic complications.

Purpose of the Study:

  • To investigate the role of AGEs in diabetic retinopathy pathogenesis.
  • To evaluate the therapeutic potential of aminoguanidine, an AGE inhibitor, in a rat model.

Main Methods:

  • Diabetic rats were treated with aminoguanidine for 26 weeks.
  • AGE accumulation, endothelial cell proliferation, and pericyte dropout were assessed.
  • Long-term effects on acellular capillaries and microaneurysms were examined after 75 weeks.

Main Results:

  • Aminoguanidine prevented AGE accumulation at arteriolar branch points.
  • The treatment completely inhibited abnormal endothelial cell proliferation.
  • Aminoguanidine significantly reduced pericyte dropout and prevented microaneurysm formation.

Conclusions:

  • AGE accumulation is a significant contributor to the development of diabetic retinopathy.
  • Aminoguanidine effectively mitigated key pathological features of diabetic retinopathy in rats.
  • These findings suggest aminoguanidine as a potential therapeutic agent for diabetic retinopathy.

More Related Videos

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice04:36

An Assay to Detect Protection of the Retinal Vasculature from Diabetes-Related Death in Mice

Published on: January 12, 2024

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...